FT
RARE icon

Fiduciary Trust’s Ultragenyx Pharmaceutical RARE Stock Holding History

Fiduciary Trust’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$360K Buy
17,199
+931
+6% +$21K ﹤0.01% 680
2025
Q4 		$374K Buy
16,268
+3,152
+24% +$104K ﹤0.01% 650
2025
Q3 		$395K Buy
13,116
+6,139
+88% +$184K ﹤0.01% 619
2025
Q2 		$254K Buy
6,977
+55
+0.8% +$1.98K ﹤0.01% 726
2025
Q1 		$251K Buy
+6,922
New +$288K ﹤0.01% 716

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Fiduciary Trust's RARE Position: Q1 2026 in Review

Fiduciary Trust increased its Ultragenyx Pharmaceutical (RARE) stake by 5.7% in Q1 2026, buying an estimated $21K and bringing the position to 17,199 shares worth $360K. The position accounts for ﹤0.01% of the portfolio, ranked #680.

Fiduciary Trust first reported a position in RARE in Q1 2025 and has held it in 5 quarters since. The position peaked at $395K in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Fiduciary Trust held 17,199 shares of Ultragenyx Pharmaceutical worth $360K as of Q1 2026.
  • Fiduciary Trust bought 931 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $21K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Fiduciary Trust's portfolio in Q1 2026, its #680 holding.
  • Fiduciary Trust first reported a position in Ultragenyx Pharmaceutical in Q1 2025 and has held it in 5 quarters since.
  • Fiduciary Trust's Ultragenyx Pharmaceutical position peaked at $395K in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.